Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.

Also called NCT03399604

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 121 participants (enrolled count) (from the registry)
Sponsor
Liquidia Technologies, Inc. (from the registry)
Registry
  • NCT NCT03399604
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03399604. Allocation not applicable; no masking; primary purpose treatment. Start 2018-01-02 (actual); primary completion 2019-05-06 (actual). Results posted on 2024-07-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
Acronym
INSPIRE
Condition
Primary Pulmonary Hypertension
Intervention (Drug)
LIQ861 Inhaled Treprostinil
Lead sponsor
Liquidia Technologies, Inc. (class: industry)
Collaborator
Nuventra, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03399604
Content hash
5ddb34b90e7a0179ceeeba08d9944a001071f00eac31ffd70c60fc39480c1c30